Navigation Links
Synthetic Biologics to Report Third Quarter 2013 Financial Results
Date:11/7/2013

ROCKVILLE, Md., Nov. 7, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it intends to release its financial results for the third quarter ended September 30, 2013 on Thursday, November 14, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)

The Company will hold an investor conference call on Thursday, November 14, 2013, at 10:00 am EST. During the call, Jeffrey Riley, Synthetic Biologics' Chief Executive Officer, will provide a brief quarterly update of the Company's multiple sclerosis program and its anti-infective drug pipeline for infectious diseases, including its oral enzyme candidate for the prevention of C. difficile infections. C. Evan Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the third quarter ended September 30, 2013.

Interested parties should call 1-877-870-4263 (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-317-0790 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=96920. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=96920 for 30 days after the call.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Atlantic Peptides, a Synthetic Peptide Manufacturer, Unveils Its New Website for Easier Navigation
2. Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"
3. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
4. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
5. Synthetic Biologics to Report Second Quarter 2013 Financial Results
6. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
7. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
8. Synthetic Biologics to Present at OneMedForum New York 2013
9. New England Biolabs supports iGEM synthetic biology competition
10. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
11. Intrexon Organizes Around New Synthetic Biology Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a ... Seymour , MD, MPH, will present information about the company,s programs ... in New York City . ... Windsor Room at 5:30PM EST. Registered attendees can request a one ... City . --> New York City ...
(Date:2/6/2016)... McLean, VA (PRWEB) , ... February 06, 2016 , ... ... enrichment session, cost-free, for middle and high school teachers on Wednesday February 10, 2016. ... be held at the Smithsonian-Mason School of Conservation, located at 1500 Remount Road in ...
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
Breaking Biology Technology:
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. ... in West Chester, Ohio announced ... winning service staff, based in Austin, Texas ... and ability to provide modifications, installations and technical support ... , CEO of PLUS, commented, "PLUS has provided world ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... Jan. 20, 2016 A market that just ... benefit from the explosion in genomics knowledge. Learn all ... Research. A range of dynamic trends are pushing market ... personalized medicine - pharmacogenomics - pathogen evolution - next ... markets - greater understanding of the role of genetic ...
Breaking Biology News(10 mins):